Friday, 16 October 2026European Markets

FONCIERE INEA, NEPI ROCKCASTLE, Another 2 Companies Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - fonciere inea (inea.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
fonciere inea (inea.pa) €32.60 8.97% 3.58%
nepi rockcastle (nrp.as) €6.70 8.41% 11.62%
cbo territoria (cbot.pa) €3.71 6.86% 5.88%
bassac (bass.pa) €41.60 3.54% 8.26%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. fonciere inea (inea.pa)

8.97% forward dividend yield and 3.58% return on equity

fonciere inea s.a., a real estate investment company, engages in owning and managing business real estate properties in france. as of december 31, 2010, its property portfolio consisted of 111 buildings. the company was founded in 2005 and is based in paris, france.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.58%.

more news about fonciere inea.

2. nepi rockcastle (nrp.as)

8.41% forward dividend yield and 11.62% return on equity

nepi rockcastle n.v. (“the company”, “nepi rockcastle”, “the group”) is a public limited company domiciled in the netherlands, having its registered office at strawinskylaan 563, wtc zuidas, tower ten, 5th floor, 1077 xx amsterdam, with registration number at the dutch chamber of commerce 87488329. the company's shares are listed on the main board of the johannesburg stock exchange limited (“jse”), euronext amsterdam and a2x. nepi rockcastle is the premier owner and operator of shopping centres in central and eastern europe (“cee”). the group benefits from a highly-skilled internal management team which combines asset management, development, investment, leasing and financial expertise.

earnings per share

as for profitability, nepi rockcastle has a trailing twelve months eps of €0.75.

pe ratio

nepi rockcastle has a trailing twelve months price to earnings ratio of 8.93. meaning, the purchaser of the share is investing €8.93 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.62%.

moving average

nepi rockcastle's value is higher than its 50-day moving average of €6.38 and way higher than its 200-day moving average of €5.81.

dividend yield

as stated by morningstar, inc., the next dividend payment is on mar 13, 2024, the estimated forward annual dividend rate is 0.51 and the estimated forward annual dividend yield is 8.41%.

more news about nepi rockcastle.

3. cbo territoria (cbot.pa)

6.86% forward dividend yield and 5.88% return on equity

cbo territoria sa engages in the urban planning and development, and property development and investment activities in france. the company develops and sells housings, retail parks, offices, industrial premises, shops, plots of land, business premises, and warehouses. it is also involved in the leisure, catering, marketing, and coworking businesses. cbo territoria sa was incorporated in 2004 and is headquartered in sainte-marie, france.

earnings per share

as for profitability, cbo territoria has a trailing twelve months eps of €0.43.

pe ratio

cbo territoria has a trailing twelve months price to earnings ratio of 8.63. meaning, the purchaser of the share is investing €8.63 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.88%.

revenue growth

year-on-year quarterly revenue growth declined by 11.6%, now sitting on 85.09m for the twelve trailing months.

yearly top and bottom value

cbo territoria's stock is valued at €3.71 at 12:30 est, below its 52-week high of €3.83 and higher than its 52-week low of €3.46.

volatility

cbo territoria's last week, last month's, and last quarter's current intraday variation average was a negative 0.19%, a negative 0.16%, and a positive 0.64%.

cbo territoria's highest amplitude of average volatility was 0.38% (last week), 0.45% (last month), and 0.64% (last quarter).

more news about cbo territoria.

4. bassac (bass.pa)

3.54% forward dividend yield and 8.26% return on equity

bassac société anonyme operates as a real estate development company primarily in france, belgium, germany, and spain. it offers residential buildings and houses, and commercial real estate, as well as prefabricated garages and land. the company was incorporated in 1972 and is headquartered in boulogne-billancourt, france. as of december 31, 2021, bassac société anonyme operates as a subsidiary of premier investissement sas.

earnings per share

as for profitability, bassac has a trailing twelve months eps of €5.81.

pe ratio

bassac has a trailing twelve months price to earnings ratio of 7.16. meaning, the purchaser of the share is investing €7.16 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.26%.

volatility

bassac's last week, last month's, and last quarter's current intraday variation average was a negative 0.86%, a negative 0.17%, and a positive 1.65%.

bassac's highest amplitude of average volatility was 2.62% (last week), 1.87% (last month), and 1.65% (last quarter).

more news about bassac.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com